THE DEAL, AT A GLANCE
From the announcementOrakl Oncology
01Who is involvedBacked by Norrsken VC, SingularFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedOrakl Oncology raised $34M Series A, announced 2026-11-12From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersOrakl Oncology raised a $34M Series A to expand AI cancer drug prediction.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Orakl Oncology · Financing Record
Explore source-linked visual explanations for Orakl Oncology. Unsupported claims are withheld while source review continues.
Record 15890 · Recorded date: 2026-11-12
What it does
Orakl Oncology is transforming oncology drug discovery and development to expand and improve the therapeutic arsenal available to patients.
Source: orakl-oncology.com ↗